Real-World Prevalence and Treatment of HER2-Mutant Lung Cancer
Author Information
Author(s): Waliany Sarah, Nagasaka Misako, Park Leah, Lam Clara, Jiang Zoe, Lin Feng, Neal Joel W.
Primary Institution: Massachusetts General Hospital Cancer Center
Hypothesis
What are the treatment patterns and outcomes for patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC) in a real-world setting?
Conclusion
The study found that most patients with HER2-mutant mNSCLC received platinum-based chemotherapy and had a median overall survival of 13.2 months in the first line of treatment.
Supporting Evidence
- Among 9206 patients with mNSCLC, 164 (1.78%) had HER2 mutations.
- 80.5% of patients received at least one line of treatment.
- Platinum-based chemotherapy was the most common first-line treatment at 45.5%.
Takeaway
This study looked at patients with a specific type of lung cancer and found that they mostly got chemotherapy, and many didn't live very long after starting treatment.
Methodology
This was a retrospective observational study using a US nationwide de-identified NSCLC clinico-genomic database.
Limitations
The study was descriptive with small sample sizes in treatment categories and limited follow-up time.
Participant Demographics
{"mean_age":67.3,"gender_distribution":{"female":56.7,"male":43.3},"race_distribution":{"White":63.4,"Black_or_African_American":6.1,"Asian":5.5,"Hispanic_Latino":0.0,"Unknown_other":14.0},"smoking_status":{"former_current_smokers":53.0,"never_smokers":47.0}}
Statistical Information
Confidence Interval
{"rwPFS_first_line":"5.5 (4.8, 6.2)","rwOS_first_line":"13.2 (10.6, 18.4)","rwPFS_second_line":"3.0 (2.3, 4.2)","rwOS_second_line":"8.2 (6.6, 13.2)"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website